Crucially, silencing SQLE was proven to deactivate the FAK/PI3K/Akt/mTOR pathway, indicating that targeting SQLE protein has considerable therapeutic potential for high‐risk OSA patients. The gene discussed is PTK2; the disease is obstructive sleep apnea syndrome.